Data from first cohort of five participants suggest an acceptable safety profile for AB-1003 in participants with limb-girdle muscular dystrophy (LGMD) 2I/R9, with no dose-limiting toxicities or ...
AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced it will present initial safety data from the first cohort of participants ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback